On This Page |
COVID-19 Solutions | New Products | Latest News | Coronavirus Research Webinars | COVID-19 Resources |
Bio-Rad provides a wide range of products for use in the support of COVID-19 diagnostic screening, confirmation of test results, surveillance, and therapy/vaccine research and development. From molecular testing using real-time PCR or Droplet Digital PCR, to immunology assays, our wide range of solutions provide best in class sensitivity and accuracy.
These pages list our product offerings in these areas. Some products have limited regional availability. If you have a specific question about coronavirus solutions, please contact your local sales office or representative. As we adhere to shelter-in-place guidelines worldwide, Bio-Rad continues to process orders and offer customer service and technical support.
From diagnostic solutions utilizing the most advanced Molecular and Immunology technologies to the basic research tools essential for the development of vaccines and therapies, our wide range of solutions provide best in class sensitivity and accuracy.
For COVID-19 testing, we offer the sensitive SARS-CoV-2 Droplet Digital PCR (ddPCR) Kit which is optimized for low viral load specimens and incorporates SARS-CoV-2 Standards for process monitoring from sample extraction.
For serological testing, we offer the Platelia SARS-CoV-2 Total Ab Assay, a single-test serological solution detecting the IgA, IgG and IgM responses, as well as VIROTROL SARS-CoV and local Bio-Rad sales office or representative. contact a Bio-Rad sales specialist.
The new PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit includes assay, controls, and supermix to detect SARS-CoV-2 virus in wastewater (sewage).
The Reliance SARS-CoV-2 RT-PCR Test provides real-time PCR detection of multiple RNA targets from the SARS-CoV-2 virus with great sensitivity and speed.
The Reliance SARS-CoV-2 Flu A Flu B RT-PCR Assay Kit can detect and differentiate the coronavirus from Flu A and B, targeting the coronavirus nucleocapsid, Flu A M1, and Flu B NS2 genes.
The new PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit includes assay, controls, and supermix to detect SARS-CoV-2 virus in wastewater (sewage).
Learn how we are helping customers, colleagues, and the global community during this health crisis.
Media Contact: Tina Cuccia | Corporate Communications Manager | Phone: 510-741-6063 | tina_cuccia@bio-rad.com
In this webinar, we will be discussing the immune response to SARS‑CoV2, both in the context of natural exposure to the virus as well as induced immunity from vaccination. We will also investigate the relationship between symptom severity and the longevity of acquired immunity.
You will learn about:
In this webinar, we will be discussing early research and nascent hypotheses regarding the pathophysiology of SARS‑CoV‑2 induced COVID-19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.
Discover why the potential link between cytokine release syndrome (CRS) and COVID‑19‑related deaths warrants further investigation.
In this webinar, learn more about:
This webinar will discuss:
In this webinar you learn how to:
This webinar provides an overview of the approaches that Bio-Rad is taking in the battle against COVID‑19:
Learn from our panel of experts as they discuss how one of the most exciting technologies in biomedical science — Droplet Digital PCR — is revolutionizing nucleic acid detection and quantitation in the following topics:
Learn how Bio-Rad helped the Singapore Agency for Science, Technology, and Research (A*STAR) develop their SARS-CoV-2 test kit for use in hospitals across Singapore.
The novel coronavirus identified as the causative agent of pneumonia cases first detected in Wuhan City, China in December, 2019, was officially designated as SARS-CoV-2. On March 11, 2020, WHO declared COVID-19 a global pandemic. For the latest information on the Novel Coronavirus COVID-19 / 2019-nCoV pandemic, visit the World Health Organization website:
WHO.int > Emergencies > Diseases > Coronavirus disease 2019
The US Centers for Disease Control and Prevention provides valuable information for US and global citizens. See the CDC website for the 2019 Novel Coronavirus Situation Summary, guidance for travelers, information for healthcare and public health professionals, guidance for laboratory professionals, background information, and the latest news:
CDC.gov > 2019 Novel Coronavirus
Although there are no clinical diagnostics for coronavirus 2019-nCoV currently approved by the US Food & Drug Administration (FDA), on February 4th, 2020, the FDA issued an Emergency Use Authorization to temporarily expand the use of RT-PCR assays for the identification of 2019-nCoV. For updates, see the US Food & Drug Administration website:
FDA.gov > Medical Countermeasures Initiative (MCMi) > Novel Coronavirus (2019-nCoV)
FDA.gov > Medical Countermeasures Initiative (MCMi) > Emergency Use Authorization